Abstract

Etk/Bmx, a member of the Tec family of nonreceptor tyrosine kinases, has been implicated in the regulation of various cellular processes including proliferation, differentiation, motility, and apoptosis. Here, we report the identification of Tec family kinases as the potential interacting proteins of the tumor suppressor p53 by an Src homology 3 domain array screening. Etk is physically associated with p53 through its Src homology 3 domain and the proline-rich domain of p53. Induction of p53 expression by DNA damage inhibits Etk activity in several cell types. Down-regulation of Etk expression by a specific small interfering RNA sensitizes prostate cancer cells to doxorubicin-induced apoptosis, suggesting that inhibition of Etk activity is required for apoptosis in response to DNA damage. We also show that Etk primarily interacts with p53 in the cytoplasm and that such interaction leads to bidirectional inhibition of the activities of both proteins. Overexpression of Etk in prostate cancer cells results in inhibition of p53 transcriptional activity and its interaction with the mitochondrial protein BAK and confers the resistance to doxorubicin. Therefore, we propose that the stoichiometry between p53 and the Tec family kinases in a given cell type may determine its sensitivity to chemotherapeutic drugs.

Highlights

  • DNA-damaging agents have been widely used for inducing apoptosis in tumor cells in anticancer therapy for decades

  • Tec family tyrosine kinases were identified as potential direct targets for p53 in response to DNA damage

  • Inhibition of Etk activity by p53 may be an essential step, at least in prostate cancer cells, for DNA damage-induced apoptosis based on our observations as follows

Read more

Summary

Introduction

DNA-damaging agents have been widely used for inducing apoptosis in tumor cells in anticancer therapy for decades. Induction of p53 expression by DNA damage inhibits Etk activity in several cell types.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call